AI feedback vs. human feedback >> we put it to the test ⭐️
At @GlomCon Fellowship, we care about how we teach, not just what we teach. So we studied one of the most overlooked skills: giving great feedback.
See the details here👇
https://t.co/xi4GRwsMwH
Diabetic Nephropathy (DN) with concurrent primary podocytopathy represents a distinct clinical entity characterized by nephrotic-range proteinuria, ultrastructural podocyte effacement and favorable response to immunosuppressive therapy ca. 2026 from @NDTsocial#Nephpearls#ECNeph
Early renal biopsy incorporating Foot Process Width (FPW) assessment enables targeted therapy to mitigate ESKD progression in this high-risk phenotype.
https://t.co/tdJLMh1zMd
Excited to share that our #GlomConHawaii meeting report is now published in Rare Kidney Disease!
Honored to have been part of such an incredible group and looking forward to what’s ahead and the next @GlomCon Hawaii 2026! 🌺
Thrilled to see our #GlomConHawaii meeting report officially published in Rare Kidney Disease! Proud of the hard work put in alongside amazing colleagues!
Looking forward to seeing what #GlomCon2026 has in store! 🌺☀️🌊
Most kidney trials whisper.
This one doesn’t.
@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.
eGFR at 39 weeks: -1.0% vs -7.7%.
Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis
Our publication evaluating serum phospholipase A2 receptor antibody's association with thromboembolic risk in membranous nephropathy is out. This systematic review & meta-analysis is amongst the 1st to demonstrate an association between serum anti-PLA2R Ab and thrombosis risk
🤩Check out our new Supplement on 'The Treatment Paradigm in IgAN Globally'
https://t.co/fzVCqCUawo
🧐Selected for you:
How should we approach the treatment of IgAN in 2025?
https://t.co/JKoaYtc6j5
#OpenAccess